Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Oral Presentation at the ESMO Congress 2026

Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that updated data on the Company’s [ 212 Pb]VMT-α-NET program have been accepted for presentation as detailed below at the European Society of Medical Oncology (ESMO) Congress 2026 taking place October 23 to 27, 2026 in Madrid, Spain.

ESMO plans to release further details for regular abstracts on October 19, 2026.

Presenter Abstract Title Presentation Details Thorvardur Halfdanarson, Mayo Clinic Comprehensive Cancer Center Cohort level safety and efficacy results for [ 212 Pb]VMT-α-NET in advanced somatostatin receptor subtype 2 (SSTR2+)-expressing neuroendocrine tumors (NETs): Cohorts 1–3 Abstract Number: 2396RO Session Type: Rapid Oral presentation Session Title: Rapid oral: NETs and endocrine tumours Session Date: October 23, 2026 Session Time: 4:15 – 5:45pm CEST / 10:15 – 11:45am EDT Presentation Time: 4:25 – 4:30pm CEST / 10:25 – 10:30am EDT

About [²¹²Pb]VMT-α-NET Perspective designed [ 212 Pb]VMT-α-NET to target somatostatin receptor subtype 2 (SSTR2), and to deliver the alpha-emitting radioisotope lead-212, or ²¹²Pb, to tumor sites expressing SSTR2.

The Company is conducting a multi-center, open-label, dose-escalation and dose-expansion study (clinicaltrials.gov identifier NCT05636618 ) of [ 212 Pb]VMT-α-NET in patients with unresectable or metastatic SSTR2-positive tumors who have not received prior radiopharmaceutical therapies (RPT).

Interim clinical data from the study, with a data cut-off date of April 17, 2026, were presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in May 2026 . These data included efficacy results for half of the patients in Cohort 2 and both patients in Cohort 1.

Initial efficacy data for the remaining patients in Cohort 2 and patients in Cohorts 3 and 4 are pending.

The Company plans to submit additional data for presentation at future medical conferences in 2026 and 2027.

About Perspective Therapeutics, Inc. Perspective Therapeutics, Inc. is a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body.

The Company has proprietary technology that utilizes the alpha-generating isotope 212 Pb to deliver powerful radiation specifically to cancer cells via specialized targeting moieties.

The Company is also developing complementary imaging techniques that incorporate the same targeting moieties, which provides the opportunity to personalize treatment and optimize patient outcomes.

This "theranostic" approach enables visualization of the specific tumor and subsequent treatment, potentially improving efficacy and minimizing toxicity.

The Company is advancing a portfolio of clinical-stage programs in the U.S., including VMT-α-NET (neuroendocrine tumors), VMT01 (melanoma), and PSV359 (solid tumors).

The Company is expanding its regional finished drug product candidate supply network, enabled by its proprietary 224 Ra/ 212 Pb generator platform used to manufacture clinical drug product candidates, to support the delivery of patient-ready drug product candidates for clinical trials and, if approved, commercial operations.

For more information, please visit the Company's website at www.perspectivetherapeutics.com.